
Menu
Patented Immunotherapy Candidate
Learn MoreBoard of Directors Expanded
Learn MoreDiscovery to Science-Led Public Company
Learn MoreCEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
Previous
Next
Patented Immunotherapy Candidate
Learn MoreBoard of Directors Expanded
Learn MoreThe Journey from Discovery to IPO
Learn MoreCEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
Previous
Next
Patented Immunotherapy Candidate
Board of Directors Expanded
The Journey from Discovery to IPO
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Previous
Next

Our patented approach, TLR-AD1, bolsters the body’s own immune system through cellular training; resulting in cancer-fighting cells increasing in number and intelligence.
With TLR-AD1, we will provide Novel Access to the Global market.